MedImmune announced today that Scott Carmer has joined the company as Executive Vice President of Commercial Operations. He will have responsibility for all sales, marketing, sales operations, and global marketing functions, and will also oversee commercialization of pipeline products.
"The breadth of Scott's biologics and global commercial experience is a tremendous asset to MedImmune," said Peter Greenleaf, MedImmune's president. "Our executive team looks forward to his contributions in further strengthening our commercial organization for future success."
Carmer brings to MedImmune more than 20 years of experience in the bio-pharmaceutical industry, most recently as a vice president of sales and marketing for Genentech's rheumatology franchise. He has also held senior leadership roles in both global marketing and brand management at Amgen, as well as key roles in sales, marketing, global business development, commercial operations, and managed care at GlaxoSmithKline. He received a degree in biology from the University of Kentucky.
"I am delighted to join MedImmune at this exciting time," said Carmer. "I am very enthusiastic about MedImmune's currently marketed products as well as its pipeline, and am committed to helping drive strategies to support the commercial availability of these important therapies to help patients who may benefit from them."
MedImmune, the worldwide biologics unit for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,300 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising drug candidates, MedImmune strives to deliver life-changing products, a rewarding career to our employees and a tireless commitment to improving patient health. For more information, visit MedImmune's website at www.medimmune.com.